These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25388909)

  • 21. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
    Braun J; Deodhar A; Inman RD; van der Heijde D; Mack M; Xu S; Hsu B
    Ann Rheum Dis; 2012 May; 71(5):661-7. PubMed ID: 22012970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
    Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
    Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
    Deodhar A; Braun J; Inman RD; van der Heijde D; Zhou Y; Xu S; Han C; Hsu B
    Ann Rheum Dis; 2015 Apr; 74(4):757-61. PubMed ID: 25387477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
    Inman RD; Davis JC; Heijde Dv; Diekman L; Sieper J; Kim SI; Mack M; Han J; Visvanathan S; Xu Z; Hsu B; Beutler A; Braun J
    Arthritis Rheum; 2008 Nov; 58(11):3402-12. PubMed ID: 18975305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
    Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
    Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.
    Lee YH
    Pharmacology; 2022; 107(11-12):537-544. PubMed ID: 35817017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis.
    Paccou J; Flipo RM
    Drug Des Devel Ther; 2016; 10():2255-62. PubMed ID: 27468228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis.
    Inman RD; Maksymowych WP;
    J Rheumatol; 2010 Jun; 37(6):1203-10. PubMed ID: 20231198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Meta-analysis of efficacy of anti-TNF alpha therapy in ankylosing spondylitis patients].
    Montilla Salas J; Muñoz Gomáriz E; Collantes E
    Reumatol Clin; 2007 Sep; 3(5):204-12. PubMed ID: 21794432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials.
    Ho A; Younis I; Le QA
    Semin Arthritis Rheum; 2022 Jun; 54():151996. PubMed ID: 35339841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
    J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
    Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
    Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
    Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis.
    Lee YH; Song GG
    Z Rheumatol; 2021 Oct; 80(8):776-784. PubMed ID: 32648054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.